Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Nexavar Approved In Japan For The Treatment Of Advanced Liver Cancer
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Nexavar(R) (sorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC), a type of liver cancer that accounts for 95 percent of all liver cancer cases in Japan(1). Nexavar is also currently available in Japan as an approved treatment for unresectable or metastatic renal cell carcinoma (RCC).

Take The Swine Flu Threat Seriously - British Hajj/Umrah Pilgrims Are Warned
Saudi Arabia"s warning to elderly Muslims, pregnant women and children against undertaking Hajj/Umrah pilgrimage this year in view of rapidly spreading swine flu worldwide sent a shock wave amongst Muslim community in Britain.
News of the day
More Effective Cancer Treatment And The Migration Of Modern Man From Africa To Western Eurasia
The Collaborative Research Centre 806 "Unser Weg nach Europa: Kultur-Umwelt-Interaktion und menschliche Mobilität im Späten Quartär" (Our Road to Europe: Culture-Environment-Interaction and human Mobility in the late Quaternary) will be directed by Professor Dr. JÃørgen of the Department of Pre- and Protohistoric Archaeology. This research centre is looking at the mobility of populations in the last 190,000 years. The focus of research will be the journey of modern man from Africa to Western Eurasia and Europe, in particular. Migration processes, and the exchange of ideas, technology and culture that entails, are an important prerequisite for important developments. The centre"s main aim is to research, using scientific and archaeological methods, how human behaviour, the climate and the environment influenced important population movements. The scientists particularly want to examine the impacts that these factors have had on the actions and reactions of populations such as emigration, immigration and adaptation to new environments. Other universities and institutions are also involved the project. These include: the University of Bonn; RWTH Aachen University; Heidelberg University; the University of Duisburg-Essen as well as the Rhineland Regional Council; the Rheinisches Amt fÃør Bodendenkmalpflege (Rheinland Department for the Preservation and Care of Field Monuments) as well as the Neanderthal Museum in Mettmann.
Sexual Health

Phase III Data Showed Novartis Investigational Bronchodilator QAB149 Significantly Improved Lung Function In COPD Patients

The Novartis investigational bronchodilator QAB149 (indacaterol) met the primary efficacy endpoints of improved lung function compared to placebo at 12 weeks in three pivotal phase III studies in chronic obstructive pulmonary disease (COPD) patients. In secondary endpoints of these studies, QAB149 demonstrated clinically relevant lung function improvements within five minutes of the first dose, lasting for 24 hours in COPD patients. The QAB149 data, which were presented at the American Thoracic Society (ATS) 2009 International Conference in San Diego, are the first from the Phase III INVOLVE, INHANCE and INLIGHT-1 trials. These were three multinational, multi-center, randomized, double-blind, placebo-controlled studies in over 3,800 patients with moderate-to-severe COPD. "Current management of COPD focuses on the use of bronchodilators to optimize lung function," said Professor Stephen I. Rennard, Pulmonary and Critical Care Medicine, University of Nebraska Medical Center. "As presented at the ATS meeting, QAB149 is a long-acting beta-agonist bronchodilator given once daily that significantly improved both airflow and clinical outcomes. The ability to provide bronchodilation on a once-daily basis will be an important addition to the current therapeutic armamentarium in COPD." In the six-month INHANCE trial, QAB149 150÷µg and 300÷µg doses significantly improved lung function at 12 weeks compared to placebo. Improvements [measured by difference in trough forced expiratory volume in one second (FEV1 )] were observed after one day (110mL and 140mL), at the 12 week primary endpoint (both doses 180mL), and at 26 weeks (160mL and 180mL). Results were statistically significant (p Novartis Pharmaceuticals Corporation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009